Why carry out this study?
|
Hidradenitis suppurativa has been associated with higher cardiovascular risk. No studies have evaluated cardiovascular risk reduction in patients with hidradenitis suppurativa under active treatment. |
The study aimed to evaluate if TNF blockade could lead to an improved cardiovascular risk in patients with severe hidradenitis suppurativa. |
What was learned from the study?
|
Adalimumab treatment might benefit a subset of patients in terms of cardiovascular risk reduction, specifically patients with classical cardiovascular risk factors, subclinical atherosclerosis, and less inflammatory load. |
TNF blockade could be of interest to improve cardiovascular risk in selected patients with hidradenitis suppurativa. |
Introduction
Methods
Design
Patients
Ethics
Inclusion Criteria
Exclusion Criteria
Variables of Interest
Main Variables
Other Variables
Statistical Analysis
Results
Sociodemographic and Basal Clinical Features of the Sample
Variables All patients (n = 27) | |||
---|---|---|---|
Age (years) | 37.59 (SD 13.68) | Sex (male) | 66.6% (18/27) |
Age at onset (years) | 21.96 (SD 10.31) | Number of areas affected | 4.23 (SD 1.96) |
Disease duration (years) | 16.4 (SD 15.5) | Dissecting cellulitis of the scalp (%) | 3.8% (1/27) |
Family history of HS (%) | 37% (10/27) | Acne conglobate (%) | 25.9% (7/27) |
Previous biologic treatment (%) | 0% (0/27) | Pilonidal sinus (%) | 33.3% (9/27) |
Previous surgical interventions for HS (%) | 33.3% (9/27) | Basal IHS4 index | 19.48 (SD 8.11) |
Hurley stage (%) | I: 11.1% (3/27) | II: 37% (10/27) | III: 51.8% (14/27) |
Distribution of Cardiovascular Risk Markers in the Sample
Cardiovascular risk markers All patients (n = 27) | |||
---|---|---|---|
Diabetes mellitus (%) | 3.7% (1/27) | Dyslipidemia (%) | 7.4% (2/27) |
Basal glycemia (mg/dL) | 87.48 (SD 12.46) | Triglycerides (mg/dL) | 125.55 (SD 59.32) |
Basal insulin (μU/mL) | 12.84 (SD 10.07) | HDL (mg/dL) | 48.11 (SD 11.65) |
HOMA index | 2.83 (SD 2.22) | High blood pressure (%) | 11.1% (3/27) |
HbA1c (%) | 5.52 (SD 0.36) | Systolic blood pressure (mmHg) | 127.56 (SD 5.96) |
Tobacco (cig/day) | 2.55 (SD 6.41) | Diastolic blood pressure (mmHg) | 83.91 (SD 6.89) |
Obesity (%) | 33.3% (9/27) | Metabolic syndrome (%) | 25.9% (7/27) |
Body mass index (kg/m2) | 39.60 (SD 8.25) | Intima–media Thickness (μm) | 633.92 (SD 120.63) |
Evolution of Disease Severity and Other Clinical Features After Adalimumab Treatment
Evolution of Carotid IMT Under Adalimumab Treatment and Predictors of IMT Responders
IMT responders (n = 11) | IMT non responders (n = 16) | p value | |
---|---|---|---|
Age (years) | 37.6 (SD 3.4) | 38.75 (SD 4.2) | 0.98 |
Sex (female) | 36.3% (4/11) | 31.2% (5/16) | 0.78 |
Disease duration (years) | 13.09 (SD 4.71) | 18.75 (SD 3.90) | 0.36 |
Acne conglobate (%) | 28.5% (2/11) | 31.2% (5/16) | 0.38 |
Diabetes mellitus (%) | 9.09% (1/11) | 0% (0/16) | 0.18* |
Basal HOMA index | 2.72 (SD 0.69) | 2.60 (SD 0.57) | 0.89 |
Basal HbA1c levels | 5.65 (SD 0.10) | 5.43 (SD 0.08) | 0.12* |
High blood pressure (%) | 18.1% (2/11) | 6.2% (1/16) | 0.36 |
Dyslipidemia (%) | 18.1% (2/11) | 0% (0/16) | 0.05* |
Tobacco consumption (cig/day) | 5.2 (SD 2.85) | 1.53 (SD 1.7) | 0.14* |
Basal IHS4 score | 17.18 (SD 2.42) | 21.06 (SD 2.01) | 0.22 |
32-week IHS4 score | 8.0 (SD 3.01) | 9.75 (SD 2.49) | 0.65 |
IHS4-55 responders (%) | 72.7% (8/11) | 68.7% (11/16) | 0.97 |
Basal BMI (kg/m2) | 31.28 (SD 2.5) | 28.5 (SD 2.07) | 0.19 |
Metabolic syndrome criteria (ATPIII) (%) | 27.3% (3/11) | 25% (4/16) | 0.89 |
C-reactive protein (mg/dL) | 18.1 (SD 8.09) | 7.9 (SD 6.60) | 0.17* |
32-week C-reactive protein (mg/dL) | 4.45 (SD 5.61) | 8.41 (SD 4.42) | 0.58 |
Basal IMT (μm) | 673.36 (SD 35.6) | 606.81 (SD 29.55) | 0.08* |